Samsung Biologics’ profit near doubles on strong orders
Jae-Young Han
Jan 29, 2023 (Gmt+09:00)
Samsung Biologics Co., the world’s top contract drugmaker, said its profit almost doubled last year thanks to more orders as its sales surged after acquiring a nearly 50% stake in a biosimilar joint venture with Biogen Inc.
Samsung Biologics on Friday reported an operating profit of 983.6 billion won ($796.4 million) in 2022 on a consolidated basis, up 83% from the previous year, with sales soaring 91% to 3 trillion won.
On a separate basis, Samsung Biologics said its operating profit jumped 80% to 968.1 billion won as sales leaped 55% to a record high of 2.4 trillion won.
The company secured deals worth $1.4 billion last year, increasing its accumulated orders to $9.5 billion.